Licensing Opportunities

Utrecht Holdings has several active licensing opportunities available for partnering. They are based on inventions for which a patent application has been filed. Non-confidential information about each opportunity is disclosed in a licensing opportunity description.

If you want more information, you can contact the person indicated in the opportunity description to make an appointment. Signing a confidential disclosure agreement may be a condition to get detailed information on the licensing opportunity.

Novel CD20 mAbs

D20 is a notoriously difficult antigen to raise immune responses to and hence only few high affinity monoclonal antibodies exist, amongst which the clinically used rituximab (Rituxan) and ofatumumab (Arzerra). In search for even better monoclonal antibodies the research group of Dr. J.H.W. Leusen of the Immunotherapy group at the UMC Utrecht used a novel immunization protocol, which yielded surprisingly high numbers of responders, never seen before. Extensive characterization of the newly obtained hybridomas showed that the panel of mAbs contain unique types of high affinity antibodies, that incorporate all required effector functions needed for clinical efficacy.

The panel was tested for apoptosis induction of tumor cells, complement activation and antibody dependent cellular cytotoxicity (ADCC) and showed high efficacies, some antibodies even better than clinical CD20 antibodies. Sequences and epitope mapping is available.

Isolated antibodies or Hybridomas are available for licensing.

Inventors

Leusen J.H.W.

Applicant

UMC Utrecht Holding B.V.

Liaison

Bas Nagelkerken
bas.nagelkerken@utrechtholdings.nl
030 253 3621

View

Cardiac coronary artery bypass implant

Technology

Background

Over 500k bypass surgeries are performed globally on the coronary arteries. Off-pump, minimally invasive surgery, and / or robot-assisted surgery hold promises for further reduction of complications and increasing efficiency.

Our discovery/invention

A cardiac bypass technology that aims to further reduce complications and improve efficiency in the cardiac surgery field. The technology has been extensively tested pre-clinically, and is prepared for first in man studies.

 Applications

Cardio-thoracic surgery;

Minimally invasive cardiac surgery;

Robot-assisted cardiac surgery.

Intellectual Property

The invention has been claimed in multiple patents.

Party

UMC Utrecht Holding B.V., The Netherlands, is owner of the patent application and is offering the technology and associated intellectual property rights. Confidential information can be exchanged after signing a confidentiality agreement.

Contact

For more information please refer to

Jaap de Bruin, +31 6 11 31 34 34

Jaap.debruin@utrechtholdings.nl

Genoveva Heldens, +31 6 11 44 24 15

Genoveva.heldens@utrechtholdings.nl

Utrecht Holdings

Yalelaan 40

3584CM Utrecht

The Netherlands

 

Julius Research Toolbox

Technology

Background

The Julius Research Toolbox is a research software infrastructure for use in human subject studies (like medical) that require self-reporting of health or behaviour. It enables 1) comprehensive research data collection by means of a customized, user-friendly study app available to participants 2) Interactive App content allowing additional “Tasks” to be initiated in response to the entered data 3) Personal access to the  App-collected data with attractive visualisation  in a participant web-portal, 4) Real-time monitoring of all and individual study-participants by researchers through a researcher portal, 5) secure research data storage and easy data extraction for analysis.

Our discovery/invention/solution

A software platform that offers a scientifically validated and integrated solution for setting up longitudinal medical studies with the use of interactive app technology.

 Applications

The JR Toolkit: 1) keeps participants engaged in self-reporting, 2) allows researchers to monitor participants real-time in an efficient and low cost way and 3) provides efficient methods of research data collection, structuring and storage 4) is already in use at UMC Utrecht, Wilhemlina Kinderziekenhuis and RIVM

Intellectual Property

The tool and software are protected by copyright.

Party

UMC Utrecht is owner of the copyrights and know how.

Contact

For more information please refer to:

Mirko Lukács, +31 (0)6 2926 9930

mirko.lukacs@utrechtholdings.nl

Utrecht Holdings

Yalelaan 40

3584CM Utrecht

The Netherlands